Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma.

Algarín EM, Díaz-Tejedor A, Mogollón P, Hernández-García S, Corchete LA, San-Segundo L, Martín-Sánchez M, González-Méndez L, Schoumacher M, Banquet S, Kraus-Berthier L, Kloos I, Derreal A, Halilovic E, Maacke H, Gutiérrez NC, Mateos MV, Paíno T, Garayoa M, Ocio EM.

Haematologica. 2019 Jul 18. pii: haematol.2018.212308. doi: 10.3324/haematol.2018.212308. [Epub ahead of print]

2.

AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy.

Bertran-Alamillo J, Cattan V, Schoumacher M, Codony-Servat J, Giménez-Capitán A, Cantero F, Burbridge M, Rodríguez S, Teixidó C, Roman R, Castellví J, García-Román S, Codony-Servat C, Viteri S, Cardona AF, Karachaliou N, Rosell R, Molina-Vila MA.

Nat Commun. 2019 Apr 18;10(1):1812. doi: 10.1038/s41467-019-09734-5.

3.

Author Correction: Cancer-associated fibroblasts induce metalloprotease-independent cancer cell invasion of the basement membrane.

Glentis A, Oertle P, Mariani P, Chikina A, El Marjou F, Attieh Y, Zaccarini F, Lae M, Loew D, Dingli F, Sirven P, Schoumacher M, Gurchenkov BG, Plodinec M, Vignjevic DM.

Nat Commun. 2018 Mar 7;9(1):1036. doi: 10.1038/s41467-018-03304-x.

4.

Cancer-associated fibroblasts induce metalloprotease-independent cancer cell invasion of the basement membrane.

Glentis A, Oertle P, Mariani P, Chikina A, El Marjou F, Attieh Y, Zaccarini F, Lae M, Loew D, Dingli F, Sirven P, Schoumacher M, Gurchenkov BG, Plodinec M, Vignjevic DM.

Nat Commun. 2017 Oct 13;8(1):924. doi: 10.1038/s41467-017-00985-8. Erratum in: Nat Commun. 2018 Mar 7;9(1):1036.

5.

Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies.

Schoumacher M, Burbridge M.

Curr Oncol Rep. 2017 Mar;19(3):19. doi: 10.1007/s11912-017-0579-4. Review.

6.

Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.

Carita G, Frisch-Dit-Leitz E, Dahmani A, Raymondie C, Cassoux N, Piperno-Neumann S, Némati F, Laurent C, De Koning L, Halilovic E, Jeay S, Wylie A, Emery C, Roman-Roman S, Schoumacher M, Decaudin D.

Oncotarget. 2016 Jun 7;7(23):33542-56. doi: 10.18632/oncotarget.9552.

7.

Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status.

Schoumacher M, Le Corre S, Houy A, Mulugeta E, Stern MH, Roman-Roman S, Margueron R.

Nat Med. 2016 Jun 7;22(6):577-8. doi: 10.1038/nm.4098. No abstract available.

PMID:
27270772
8.

ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor.

Mounir Z, Korn JM, Westerling T, Lin F, Kirby CA, Schirle M, McAllister G, Hoffman G, Ramadan N, Hartung A, Feng Y, Kipp DR, Quinn C, Fodor M, Baird J, Schoumacher M, Meyer R, Deeds J, Buchwalter G, Stams T, Keen N, Sellers WR, Brown M, Pagliarini RA.

Elife. 2016 May 16;5. pii: e13964. doi: 10.7554/eLife.13964.

9.

The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma.

Amirouchene-Angelozzi N, Frisch-Dit-Leitz E, Carita G, Dahmani A, Raymondie C, Liot G, Gentien D, Némati F, Decaudin D, Roman-Roman S, Schoumacher M.

Oncotarget. 2016 Apr 26;7(17):23633-46. doi: 10.18632/oncotarget.8054.

10.

Upcoming translational challenges for uveal melanoma.

Amirouchene-Angelozzi N, Schoumacher M, Stern MH, Cassoux N, Desjardins L, Piperno-Neumann S, Lantz O, Roman-Roman S.

Br J Cancer. 2015 Dec 22;113(12):1746. doi: 10.1038/bjc.2015.456. No abstract available.

11.

Upcoming translational challenges for uveal melanoma.

Amirouchene-Angelozzi N, Schoumacher M, Stern MH, Cassoux N, Desjardins L, Piperno-Neumann S, Lantz O, Roman-Roman S.

Br J Cancer. 2015 Nov 3;113(9):1249-53. doi: 10.1038/bjc.2015.269. Epub 2015 Oct 27. Review. Erratum in: Br J Cancer. 2015 Dec 22;113(12):1746.

12.

Conditional expression of fascin increases tumor progression in a mouse model of intestinal cancer.

Schoumacher M, El-Marjou F, Laé M, Kambou N, Louvard D, Robine S, Vignjevic DM.

Eur J Cell Biol. 2014 Oct;93(10-12):388-95. doi: 10.1016/j.ejcb.2014.08.002. Epub 2014 Sep 16.

PMID:
25269996
13.

Inhibiting Tankyrases sensitizes KRAS-mutant cancer cells to MEK inhibitors via FGFR2 feedback signaling.

Schoumacher M, Hurov KE, Lehár J, Yan-Neale Y, Mishina Y, Sonkin D, Korn JM, Flemming D, Jones MD, Antonakos B, Cooke VG, Steiger J, Ledell J, Stump MD, Sellers WR, Danial NN, Shao W.

Cancer Res. 2014 Jun 15;74(12):3294-305. doi: 10.1158/0008-5472.CAN-14-0138-T. Epub 2014 Apr 18.

14.

Basement membrane invasion assays: native basement membrane and chemoinvasion assay.

Schoumacher M, Glentis A, Gurchenkov VV, Vignjevic DM.

Methods Mol Biol. 2013;1046:133-44. doi: 10.1007/978-1-62703-538-5_8.

PMID:
23868586
15.

ETV5 cooperates with LPP as a sensor of extracellular signals and promotes EMT in endometrial carcinomas.

Colas E, Muinelo-Romay L, Alonso-Alconada L, Llaurado M, Monge M, Barbazan J, Gonzalez M, Schoumacher M, Pedrola N, Ertekin T, Devis L, Ruiz A, Castellvi J, Doll A, Gil-Moreno A, Vazquez-Levin M, Lapyckyj L, Lopez-Lopez R, Robine S, Friederich E, Castro M, Reventos J, Vignjevic D, Abal M.

Oncogene. 2012 Nov 8;31(45):4778-88. doi: 10.1038/onc.2011.632. Epub 2012 Jan 23.

PMID:
22266854
16.

New functional poly(N-vinylpyrrolidone) based (co)polymers via photoinitiated cobalt-mediated radical polymerization.

Debuigne A, Schoumacher M, Willet N, Riva R, Zhu X, Rütten S, Jérôme C, Detrembleur C.

Chem Commun (Camb). 2011 Dec 21;47(47):12703-5. doi: 10.1039/c1cc15471k. Epub 2011 Oct 28.

PMID:
22037581
17.

Cytoskeleton networks in basement membrane transmigration.

Schoumacher M, Louvard D, Vignjevic D.

Eur J Cell Biol. 2011 Feb-Mar;90(2-3):93-9. doi: 10.1016/j.ejcb.2010.05.010. Epub 2010 Jul 6. Review.

PMID:
20609495
18.

Actin, microtubules, and vimentin intermediate filaments cooperate for elongation of invadopodia.

Schoumacher M, Goldman RD, Louvard D, Vignjevic DM.

J Cell Biol. 2010 May 3;189(3):541-56. doi: 10.1083/jcb.200909113. Epub 2010 Apr 26.

19.

Epithelial morphogenesis and intestinal cancer: new insights in signaling mechanisms.

Fre S, Vignjevic D, Schoumacher M, Duffy SL, Janssen KP, Robine S, Louvard D.

Adv Cancer Res. 2008;100:85-111. doi: 10.1016/S0065-230X(08)00003-1. Review.

PMID:
18620093
20.

Fascin, a novel target of beta-catenin-TCF signaling, is expressed at the invasive front of human colon cancer.

Vignjevic D, Schoumacher M, Gavert N, Janssen KP, Jih G, Laé M, Louvard D, Ben-Ze'ev A, Robine S.

Cancer Res. 2007 Jul 15;67(14):6844-53.

21.
22.

A cluster of HIV infection among heterosexual people without apparent risk factors.

Clumeck N, Taelman H, Hermans P, Piot P, Schoumacher M, De Wit S.

N Engl J Med. 1989 Nov 23;321(21):1460-2.

PMID:
2811959

Supplemental Content

Loading ...
Support Center